CMS Open Payments · Program Year 2024
Janssen Scientific Affairs, LLC
Janssen Scientific Affairs, LLC reported $11,005,380.96 across General Payments, Research, and Ownership to 9,610 physicians and teaching hospitals across 10,110 transactions.
- $11.0M
- All-tracks total
- 10,110
- Transactions
- 9,610
- Recipients
- −$469.4K
- General Payments vs PY2023
Janssen Scientific Affairs, LLC reported $11,005,380.96 across all CMS Open Payments tracks (General + Research + Ownership) to 9,610 physicians and teaching hospitals in Program Year 2024 - ranking #157 of 1,925 reporting manufacturers (0.1% of the all-tracks industry total); General Payments alone were $5,710,669.41, averaging $1.1K per recipient.
Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.
CMS Sunshine Act warrant
Manufacturer janssen-scientific-affairs-llc Janssen Scientific Affairs, LLC
$11.0M · #157/1,925 · 0.1% industry · PY2024
- TOT $11.0M
- RANK #157
- SHARE 0.1%
- TXN 10,110
- RCP 9,610
- CAT 7
- GEN $5.7M
- ΔGEN −$469.4K
- TOP1 22.9%
- PY 2024
Volume peers
Nearest volume peer: Mesh Suture Inc ($10.8M)
Janssen Scientific Affairs, LLC sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →
Release-over-release change
General Payments changed from PY2023 to PY2024
Janssen Scientific Affairs, LLC's CMS-reported General Payments decreased by $469.4K (−7.6%) from PY2023 to PY2024.
How this year-over-year comparison is scoped
The comparison uses consecutive CMS program years only (current = prior + 1) from the manufacturer General Payments summary and excludes research and ownership or investment records. Non-consecutive year pairs are not shown as year-over-year change. This General Payments figure is not the all-tracks company total in the hero.
CMS source labels for this exact identifier: PY2022: JANSSEN SCIENTIFIC AFFAIRS, LLCPY2023: JANSSEN SCIENTIFIC AFFAIRS, LLCPY2024: Janssen Scientific Affairs, LLC. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.
Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.
General Payments: PY2023 vs PY2024
Annual CMS-reported totals for this company, not an all-category Open Payments total
- PY2023
- $6,180,045.60
- PY2024
- $5,710,669.41
What the Data Shows for Janssen Scientific Affairs, LLC
Rank #157 of 1,925 companies in CMS Open Payments for 2024 belongs to Janssen Scientific Affairs, LLC, which reported $11,005,380.96 across 10,110 transactions to 9,610 recipients - a comparatively small 0.1% slice of all industry payments reported nationwide for the year. Averages work out to $1.1K per transaction and $1.1K per recipient.
The 7-category breakdown below covers general payments only (see our methodology for how research and ownership payments are reported separately). The largest general-payment category is "Consulting Fee" at $2.0M, accounting for 34.3% of this company's General Payments and 1,166 transactions.
General Payment Breakdown by Type
"Consulting Fee" leads Janssen Scientific Affairs, LLC's 7-category general-payment breakdown at $2.0M, 34.3% of the reported total.
Janssen Scientific Affairs, LLC reports 7 general-payment categories - the top three are Consulting Fee (34.3%), Grant (25.1%), and Compensation for Services Other Than Consulting (24.0%). The remaining 4 categories make up 16.6% of this company's reported general-payment total. That multi-category mix is the kind of profile single-category reporters cannot show.
How Janssen Scientific Affairs, LLC divides its payments
How the reported total splits across payment categories
| Payment Type | Amount | Transactions | % of Total |
|---|---|---|---|
| Consulting Fee | $2.0M | 1,166 | 34.3% |
| Grant | $1.4M | 37 | 25.1% |
| Compensation for Services Other Than Consulting | $1.4M | 21 | 24.0% |
| Food and Beverage | $561.7K | 7,776 | 9.8% |
| Royalty or License | $210.9K | 1 | 3.7% |
| Travel and Lodging | $162.3K | 596 | 2.8% |
| Honoraria | $13.6K | 13 | 0.2% |
Recipient Concentration in General Payments
The five largest recipient relationships account for $2,448,521.97 (42.9%) of $5,710,669.41 in this company's General Payments records across 6,006 recipients.
General Payments scope note
Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.
Largest General-Payment relationships for Janssen Scientific Affairs, LLC
The five named recipients with the highest reported General Payments from this company
- 1
Neil Howard Love
$1,310,000.00 across 17 reported transactions
- 2
Rush University Medical Center
$582,649.00 across 11 reported transactions
- 3
Montefiore Medical Center
$260,000.00 across 3 reported transactions
- 4
Denver Health Medical Center
$210,872.97 across 1 reported transactions
- 5
Henry Ford Hospital
$85,000.00 across 1 reported transactions
Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.
Similarly Concentrated Companies
Companies whose General Payments are spread across recipients about as (un)evenly as Janssen Scientific Affairs, LLC's, measured by the same HHI concentration index above, not by payment size.
What HHI 2,500 means here
2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about Janssen Scientific Affairs, LLC.
Companies with Similar Payment Volumes
Open a profile or compare a similar company's CMS-reported payment pattern with Janssen Scientific Affairs, LLC.
Showing 6 of 1,924 companies with CMS-reported payment data.
Glaukos Corporation
Alafair Biosciences, Inc.
Abiomed
TG Therapeutics, Inc.
Ortho-Clinical Diagnostics, Inc.
Disclaimer
This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.